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Many human tumor cells are characterized by overexpression or mutation of epidermal growth factor receptor (EGFR). Emerging 
evidence indicates that EGFR, as well as some of its downstream components, can translocate to the nucleus and play roles in 
transcriptional regulation, signaling conduction and repair of DNA double strands breaks (DSBs). EGFR in its nuclear manifesta-
tion promotes DSB repair by interacting with proteins including DNA-PK, ATM, Rad51 and BRCA1, involved in DSB repair, via 
the PI3K-Akt and Ras-Raf-MAPK pathways. DNA damage repair in tumor cells is emerging as an attractive target in radiothera-
py and chemotherapy. Interruption of EGFR functions, or those of its downstream components, presents a promising strategy for 
confounding DNA damage repair in tumor cells. 
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The epidermal growth factor receptor (EGFR) belongs to 
the Type I subfamily of receptor tyrosine kinases (RTKs), 
which includes four closely related receptors: Her-1/ErbB1, 
Her-2/Neu/ErbB2, Her-3/ErbB3 and Her-4/ErbB4. EGFR is 
a 170-kD transmembrane glycoprotein composed of 1186 
aa residues. Structurally EGFR has an extracellular ligand- 
binding domain, a transmembrane domain, and an intracel-
lular tyrosine kinase domain (TKD). The function and 
downstream signaling of EGFR as a cell surface receptor 
have been documented by a substantial body of literature. It 
is becoming abundantly clear, however, that aside from its 
duties in the cell membrane, EGFR and some of its down-
stream components translocate to the nucleus where they 
have various regulatory functions, such as transcriptional 
regulation and repair processes. Among these, the function 
of nuclear EGFR as a regulator of double strands breaks 
(DSBs) is of particular importance [1]. In this article, we 
review the current knowledge regarding EGFR modulation 
of DNA damage repair.  
1  Activation and nuclear translocation of 
EGFR 
EGFR can be activated in ligand-dependent and ligand- 
independent manners. In response to genotoxic stresses, 
such as ionizing radiation (IR), cisplatin, UV light, heat 
shock and H2O2, EGFR is activated in the absence of a  
ligand and translocates to the nucleus [2,3]. Epstein-Barr 
virus (EBV)-encoded, latent membrane protein 1 (LMP1) 
has been shown to regulate the nuclear accumulation of 
EGFR in a ligand-independent manner, both quantitatively 
and qualitatively, in a nasopharyngeal carcinoma cell line, 
where it increased expression and phosphorylations of 
EGFR in a dose-dependent manner [4].  
One effect of reactive oxygen species generated by ion-
izing radiation is the inactivation of a redox-sensitive, cys-
teine-based protein-tyrosine-phosphatase, which in turn 
causes a shift in the equilibrium between phosphorylated 
and dephosphorylated forms of EGFR and stimulates the 
kinase activity of the receptor in a ligand-independent 
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manner. Another possible mechanism of EGFR activation in 
the irradiated cell is by up-regulation of autocrine/paracrine 
secretion of EGFR ligands [5].  
Upon stimulation EGFR forms homodimers or heterodi-
mers with some other ErbB family member, enabling its 
kinase activity and resulting in intermolecular phosphoryla-
tion of key tyrosine residues within the TKD and other pro-
teins involved in downstream signaling. While both    
ligand-dependent and ligand-independent phosphorylations 
of EGFR trigger intracellular signaling and receptor inter-
nalization, the fate of receptor activated by these different 
modes is different. Indeed, binding of epidermal growth 
factor (EGF), the physiological ligand, results in the inter-
nalization of EGFR into clathrin-coated pits followed by 
receptor degradation while ionizing radiation results in a 
rapid stabilization and activation of Src kinase, and subse-
quent Src-mediated phoshorylation of Tyr14 of caveolin-1 
and Tyr845 of EGFR. These phosphorylations seem to sig-
nal the formation of the caveolin/EGFR complex, a process 
which is associated with the perinuclear accumulation of 
EGFR and its persistent kinase activity. A putative nuclear 
localization sequence (NLS) of EGFR has been identified. 
Following irradiation EGFR is phosphorylated at residue 
Thr654 located within this NLS by PKCε; this phosphoryla-
tion induces binding to karyopherin  and karyopherin . 
Overall, the process enables transport through a nuclear 
pore into the nucleus. Radicals generated by ionizing radia-
tion are also involved in the induction of the transport pro-
cess [2,5–8]. A model of integral trafficking from the endo-
plasmic reticulum (ER) to the nuclear envelope (NE) 
transport (INTERNET) provides another scenario for the 
nuclear translocation of EGFR, that is, integral inner nuclear 
membrane (INM) proteins initially inserted into the ER 
membrane are targeted to the INM of the NE through the 
outer nuclear membrane (ONM) and nuclear pore complex 
(NPC). Nuclear EGFR accumulation results from a balance 
of import and export processes. Recent evidence suggests 
that nuclear export of EGFR may involve exportin chromo-
some region maintenance protein 1 (CRM1) [3,6,9]. 
2  Role of EGFR in DNA damage repair 
The most important biological effect of ionizing radiation is 
DNA damage, including single strand breaks (SSBs) and 
double strands breaks. The most lethal radiation-induced 
DNA damage is the DSBs. In higher eukaryotes, two dis-
tinct mechanisms for DSB repair complement each other to 
protect cells from radiation-induced DNA damage; these are 
nonhomologous end-joining (NHEJ) and homologous re-
combination (HR). NHEJ is operative in all phases of the 
cell cycle, but especially in G0 and G1 phases, and is the 
dominant pathway in the repair of DSBs. HR is functional 
only during the late S/G2 phases, when a sister chromatid is 
available for repair, and it plays a supportive role. These 
two repair pathways have a close relationship with the 
phosphoinositide 3-kinase related kinases (PIKKs), includ-
ing ataxia telangiectasia mutated (ATM), ATM- and Rad3- 
related (ATR) and DNA-dependent protein kinase (DNA- 
PK). EGFR modulates DSB repair primarily via NHEJ, but 
also via HR [1,10]. 
2.1  EGFR and the NHEJ mechanism 
NHEJ is the physical rejoining of DSB ends. NHEJ is cata-
lyzed by a core complex that consists of four proteins, 
DNA-PK, X-ray repair complementing defective repair in 
Chinese hamster cells 4 (XRCC4), DNA ligase IV and Ar-
temis, which further associates with a complex of three 
proteins, Mre11, Rad50, and Nbs1 (MRN), and brings about 
the physical rejoining of DSB ends [2]. NHEJ is dependent 
on DNA-PK and so called DNA-PK-dependent nonhomol-
ogous end-joinding (D-NHEJ). DNA-PK is a nuclear ser-
ine/threonine kinase whose activity is stimulated by dou-
ble-stranded DNA. DNA-PK comprises three subunits, the 
470 kD catalytic subunit (DNA-PKcs), and two regulatory 
subunits, the 70 kD Ku70 and the 80 kD Ku80 [1,2,10]. 
Phosphorylation of DNA-PKcs at Thr2609 is an essential 
prerequisite for NHEJ. The effect of EGFR on NHEJ is due 
to the redistribution and activation of DNA-PK. 
(i) The EGFR-DNA-PK complex.  DNA-PKcs and 
Ku70/ Ku80 are considered predominantly nuclear proteins, 
but there are reports that DNA-PK subunits are inde-
pendently localized in lipid rafts, where they may interact 
with membrane proteins also localized in lipid rafts. Ioniz-
ing radiation can induce translocation of DNA-PKcs from 
the nucleus to the cytosol [8]. In the human bronchial car-
cinoma cell line A549, the human squamous carcinoma cell 
line FaDu and the transformed human fibroblast cell line 
HH4dd, ionizing radiation results in a clear translocation of 
the perinuclear EGFR to the nucleus along with the nuclear 
import of Ku subunits 80 and 70 and phosphatase PP1 [5,7]. 
The EGFR-DNA-PK complex is formed in the nucleus 
during the first 5 min after irradiation, concomitant with an 
increase in activity of DNA-PK, and the maximal activity 
was detected 10 min after irradiation [7,11]. Activity of 
DNA-PK is regulated by phosphorylation and dephosphor-
ylation. Autophosphorylation of DNA-PK at Thr2609, 
Ser2612, Thr2638 and Thr2647 results in the loss of its 
protein kinase activity and dissociation of DNA-PKcs from 
the DNA-bound Ku complex. Protein phosphatases can re-
move the phosphate groups from autophosphorylated inac-
tive DNA-PKcs and restore DNA-PK protein kinase activity 
[7]. 
EGFR makes physical contact with DNA-PK and then 
forms a complex, which is associated with nuclear translo-
cation of EGFR. As a result of the anti-EGFR antibody 
C225, which binds to the extracellular domain of EGFR and 
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blocks its nuclear translocation, the complex is generated in 
the cytoplasm. This phenomenon results in a decrease in the 
nuclear activity of DNA-PK by about 75%, with a concom-
itant increase in the cytoplasmic activity of DNA-PK; this 
explains an observed decrease in the efficiency of D-NHEJ 
[11,12]. There are different opinions about whether tyrosine 
kinase inhibitors that target nuclear kinase activity of EGFR 
have an effect on the redistribution of DNA-PK. Gefitinib (a 
tyrosine kinase inhibitor) was observed to suppress nuclear 
DNA-PK levels in head and neck squamous cell carcinoma 
cells [13], but not in nonsmall cell lung carcinoma (NSCLC) 
cell lines A549 [14]. In NSCLC cell lines, unlike wild-type 
(WT) EGFR, receptors with common oncogenic TKD mu-
tations, L858R or ∆E746-E750, are more sensitive to ioniz-
ing radiation and are defective in radiation induced translo-
cation to the nucleus; receptors with these mutations fail to 
bind the catalytic and regulatory subunits of the DNA-PK. 
Cells expressing wtEGFR exhibited greater radiosensitivity 
when transfected with mtEGFR. DNA-PKcs plays a critical 
role in EGFR-mediated response to radiation, because in a 
DNA-PKcs-deficient genetic background, the radio-    
protective effect of EGFR is lost. Thus, interactions with 
DNA-PKcs constitute a critical component of EGFR-   
mediated radioprotection [8,15]. 
(ii) EGFR and phosphorylation of DNA-PK.  The 
full-length EGFR in the nucleus is a tyrosine kinase, shown 
to be capable of phosphorylating DNA-PKcs at Thr2609 
[2,7,12]. Although no blockage of nuclear EGFR transport 
by tyrosine kinase inhibitors was observed in these studies, 
a clear inhibition of DNA repair was seen. This can be ex-
plained by the crucial role of EGFR kinase activity in regu-
lation of DNA-PK or other nuclear proteins involved in 
DNA repair following irradiation [3]. 
Epidermal growth factor receptor variant III (EGFRvIII) 
is the most common type of EGFR mutation; it lacks the 
ligand-binding domain and is constitutively active. EG-
FRvIII is the most commonly amplified/mutated gene in 
glioblastoma multiforme (GBM) and is expressed in about 
40% in head and neck carcinomas. In EGFRvIII-expressing 
U87 glioma cells, radioresistance is associated with en-
hanced DSB repair kinetics. Gefitinib and a PI3K inhibitor, 
LY294002, can abrogate the accelerated DSB repair, while 
expression of constitutively active, myristylated Akt-1 ac-
celerates repair. EGFRvIII-expressing U87 glioma cells 
show elevated activation of DNA-PKcs, and enhanced radi-
oresistance can be abrogated by the DNA-PKcs-specific 
inhibitor NU7026, but EGFRvIII fails to confer radio-  
resistance in DNA-PKcs-deficient cells. There is no evi-
dence of nuclear translocation of EGFRvIII. It is therefore 
plausible that EGFRvIII expression in GBM tumor cells 
might enhance DSB repair via the canonical PI3K/Akt-1 
pathway rather than by direct physical association with 
DNA-PKcs [16]. Activation of DNA-PKcs by IR involves 
its phosphorylation at several serine/threonine residues. 
As Akt-1 is a serine/threonine kinase, it is conceivable that 
the hyperphosphorylation of DNA-PKcs in EGFRvIII-  
expressing cells may be potentiated by activated Akt-1. 
Knockdown of Akt-1 by specific siRNA blocks DNA-PKcs 
phosphorylation at Thr2609 and Ser2056 in the human 
bronchial carcinoma cell line A549 and H460 [16,17]. 
Blockade of the EGFR-dependent PI3K-Akt pathway in 
K-RAS-mutated A549 cells significantly affects postradia-
tion survival by diminishing Thr2609 phosphorylation of 
DNA-PKcs, resulting in a decreased DSB repair capacity. 
There are strikingly high levels of radiation-  induced 
Akt-1 nuclear translocation in a mouse orthotopic glioma 
model expressing EGFRvIII. Recently, a close physical 
association between Akt-1 and DNA-PKcs at sites of DSBs 
on IR has been shown. DNA-PK-mediated phosphorylation 
of Akt-1 Ser473 is a key step in activation of Akt-1, and 
results in a 10-fold enhancement of kinase activity. The 
cross talk between ATM and DNA-PKcs is probably a cen-
tral axis in the response of cells to IR-induced DNA damage 
[1,18–20]. 
Activation of the RAS/MAPK pathway is an important 
step in the EGFR-mediated radioprotection, which confers 
radioresistance by up-regulation of gene transcription in-
volved in DNA repair [21]. Ras activity is responsible for 
stimulation of PI3K-Akt signaling in response to ionizing 
radiation, but evidence also indicates an autocrine loop of 
EGFR stimulation in K-RASmt tumor cells, which activates 
PI3K-Akt signaling independently of a direct upstream 
function of K-Ras activity [22]. Constitutively activated, 
mutant Ras, especially K-Ras, can promote the Ras muta-
tion-dependent up-regulated production and secretion of 
autocrine EGFR ligands (i.e., TGF- and amphiregulin); 
these, in turn, selectively stimulate the EGFR-PI3K-Akt 
pathway and activated DNA-PKcs. 
Phosphorylation of Thr2609 in DNA-PKcs requires ATM, 
which plays important roles in DNA damage response, cell 
cycle regulation, and homologous recombination. EGFR can 
regulate the transcription of the ATM gene [20]. 
The reviewed experimental data indicate that EGFR di-
rectly activates DNA-PK as a tyrosine kinase or indirectly 
through the activation of the PI3K-Akt pathway or tran-
scriptional regulation of the ATM gene. 
There are also data suggesting that EGFR might interact 
with NHEJ via H2AX or XRCC1. Phosphorylation of 
H2AX is considered a signal for the accumulation of repair 
proteins near damaged chromatin. Consequently, blockage 
of the EGFR-PI3K-Akt pathway results in inhibition of 
phosphorylation of H2AX and thus retards this accumula-
tion impeding DNA repair [23]. XRCC1 is a cofactor of 
DNA-PKcs and plays a central role in base excision of sin-
gle-strand break repair. It has been reported that an activa-
tion of EGFR by X-irradiation resulted in a rapid up-    
regulation of XRCC1 expression, which was mediated via 
MAPK signaling [10]. 
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2.2  EGFR and the HR mechanism 
Using the sister chromatid or DNA repeats as templates, HR 
repairs DSBs. HR is initiated when the DNA single strands 
emerge after DNA strands are cut by an MRN complex. 
MRN forms complexes with replication protein A and 
Rad51; both are core proteins in the HR machinery. Several 
studies have reported that MAPK signaling regulates HR in 
human cells either positively or negatively. When ERK1/2 
signaling was stimulated by oncogenic Raf-1, an approxi-
mate 2-fold increase in HR was observed. By contrast, inhi-
bition of the p38 MAPK pathway also generated an almost 
2-fold stimulation of HR. EGFR and growth factor signal-
ing in general has long been known to modulate cell cycle 
regulation. It is well-accepted that HR is most active in late 
S-phase and G2. It is plausible, therefore, that these appar-
ently disparate changes in HR can be reconciled by consid-
ering the cell cycle phase in which they have occurred 
[18,24,25]. 
ATM protein plays a crucial role in HR. Upon DNA 
damage or alterations in chromatin structure, ATM dimers 
are quickly autophosphorylated at Ser1981, thereby activat-
ing ATM and leading to the phosphorylation of several 
downstream targets, including H2AX, p53, CHK2, Nbs1, 
hMDM2, SMC1, Rad51 and BRCA1. RAS/RAF/MEK/ 
ERK signaling is associated with phosphorylation of ATM 
at Ser1981. Inhibition of MAP/ERK kinase (MEK)/ERK 
signaling suppresses ATM phosphorylation levels >85% 
throughout the cell cycle. The ATM-specific inhibitor 
KU-55933 partly blocks radiation-induced ERK1/2 phos-
phorylation, suggesting that ATM regulates ERK1/2 sig-
naling. Thus, it seems that ATM and ERK signaling might 
be interacting in a regulatory feedback loop [25,26]. EGFR 
may affect transcription of the ATM gene by NF-κB, acti-
vated through the PI3K-Akt pathway. When NF-κB is acti-
vated it translocates to the nucleus, where it activates ATM, 
ATR and DNA-PK, thus promoting DNA damage repair 
and cell proliferation and/or inhibiting apoptosis. 
In gefitinib-pretreated A549 cells, a DNA repair protein, 
pNbs1, exhibits a more robust and prolonged activation 
after irradiation. Because Nbs1 functions in a protein com-
plex MRN, an abnormal abundance of Nbs1 may sequester 
other repair proteins away from the sites of DSBs. Nbs1 is a 
substrate for the ATM kinase; Nbs1 phosphorylation is a 
possible connection between EGFR>ERK>ATM>Nbs1, 
and should be examined in further studies [14]. 
In human breast cancer cells, blockage of EGFR by erlo-
tinib attenuates DNA damage-induced Rad51 foci and re-
sults in a substantial reduction of BRCA1 available in the 
nucleus to perform HR. Both Rad51 and BRCA1 are essen-
tial components of the HR machinery [27]. Treatment of 
NSCLC cells with gefitinib resulted in decreased levels of 
phospho-ERK1/2 and Rad51 protein and their mRNAs. The 
potent MEK inhibitor, U0126, mimicked the effects of ge-
fitinib suggesting that MEK/ERK signaling downstream of 
EGFR regulates HR by controlling the levels of Rad51 [24]. 
EGFR may affect phosphorylation of BRCA1 via the PI3K/ 
Akt pathway, because Akt-1 can directly phosphorylate 
BRCA1 on Thr509 [1]. 
EGFR may interact with proliferating cell nuclear anti-
gen (PCNA) as well as with components involved in NHEJ 
and HR. PCNA is subject to tyrosine phosphorylation at 
Tyr211 in an EGFR-dependent manner, and this phosphor-
ylation enhances PCNA stability on chromatin. PCNA is an 
essential protein for DNA synthesis, damage repair and cell 
proliferation. Isoforms of PCNA, including Rad9, Hus1 and 
Rad1, assemble in a homotrimeric ring structure encircling 
the DNA double helix; in this format it functions as a sensor 
for DNA damage and is involved in DNA replication. 
Phospho-PCNA is correlated with nuclear EGFR in human 
breast cancer tumor samples and has a strong prognostic 
value for breast cancer patients survival. Nuclear EGFR is 
also positively correlated with the expression of PCNA in 
oral squamous cancer [28]. 
In summary, EGFR promotes DSB repair by interacting 
with proteins that implement NHEJ and HR, including 
DNA-PK, ATM, Rad51 and BRCA1 (in every case as the 
nuclear translocated version), via the PI3K-Akt and 
Ras-Raf-MAPK pathways (Figures 1 and 2). 
3  Future prospects 
DNA repair is emerging as an attractive pharmacological 
target in chemotherapy and radiotherapy. Although many 
solid tumors may escape the process of apoptosis, the 
 
 
Figure 1  Mechanisms that have been identified to explain how EGFR 
signaling interacts with NHEJ. Upon ionizing irradiation, EGFR modulates 
the activity of DNA-PK, a key component in NHEJ, by various means: (1) 
EGFR translocates to the nucleus and forms a complex with DNA-PK; (2) 
EGFR activates DNA-PK directly as a tyrosine kinase; (3) EGFR activates 
DNA-PK through the activation of the PI3K/Akt pathway; (4) EGFR regu-
lates the transcription of ATM and XRCC1 genes, which are associated with 
DNA-PK via the ERK pathway. 
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Figure 2  Mechanisms that have been identified to explain how EGFR 
signaling interacts with HR. EGFR regulates the activity and transcription 
of ATM, BRCA1 and Rad51 mainly through the RAS/RAF/MEK/ERK 
pathway and PI3K/Akt pathways. 
mechanisms underlying DNA damage repair remain fun-
damentally the same as those in normal cells. Inhibitors that 
target DNA-PK (NU7441) and ataxia telangiectasia-   
mutated (KU55933), have shown promising results in aug-
menting the effects of radiation in preclinical studies and 
clinical trials. Disruption of EGFR nuclear import also 
compromises DNA repair and tumor survival. A therapeutic 
strategy that disrupts EGFR nuclear import or abrogates 
EGFR-DNA-PKcs interactions could potentially be tu-
mor-specific, sparing normal tissue. EGFR expression neg-
atively correlates with the outcomes of radiotherapy in 
EGFR-overexpressed head and neck carcinomas. A greater 
molecular understanding of the novel connections between 
EGFR signaling and DSB repair should fuel the develop-
ment of even more refined radiosensitizing approaches in 
the future. 
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